

December 2007

## Maryland Department of Health and Mental Hygiene / Office of Systems, Operations and Pharmacy

## Emergency Supply of Medications

All Maryland Medical Assistance recipients are entitled to receive a 72-hour supply of medicine (30-day supply for Atypical Antipsychotic drugs) while awaiting prior authorization or approval to dispense a nonformulary, non-preferred or brand name medication for which there is a generic equivalent. A 30-day supply is allowed for atypical antipsychotic agents subject to step therapy, this includes Zyprexa ${ }^{\oplus}$ as of January 1, 2008. If the prescriber is unavailable to either change the medication or obtain preauthorization, or if the prior authorization process is not completed (the State is required to respond to all requests for prior authorization within 24 hours), all Maryland Medicaid HealthChoice managed care organizations (MCOs) and the Maryland Medicaid fee-for-service Pharmacy Program will cover a minimum 72 -hour supply of drugs. Pharmacists should use their professional judgment in determining whether the prescription is needed on an emergency basis.
The recipient may present mobility or access issues that make returning to the pharmacy very difficult or expensive. The pharmacist should take this factor into consideration when deciding whether or not to dispense an emergency supply.

When a "prior authorization required" denial is received, the pharmacy should contact the prescriber to either change the medication or have the prescriber obtain necessary prior authorization. It would be beneficial if the pharmacist can advise the prescriber of the alternative drugs that are preferred and do not require preauthorization. Normally the prescriber can obtain authorization with a phone call. If not, and delays in the authorization process increase risk for the patient, the prescriber can request the pharmacist to dispense an emergency supply.

It will be necessary for the pharmacist to request authorization to dispense an emergency supply of a prescription by calling a $24 / 7$ telephone number. In the case of sprays, inhalers, eye or ear drops, creams, ointments, antibiotics etc., it may be necessary to dispense the entire prescription as an emergency supply due to the way the drug is packaged or administered (see Advisory No. 7, page 3).

For HealthChoice MCO and PAC members' non-mental health and non-antiretroviral drugs, the pharmacist must contact the appropriate Pharmacy Benefit Manager and follow their procedures before dispensing an emergency supply. The contact information for these is given on the web at bttp://www.marylandmedicaidpharmacyinformation.com/ Formularies.htm.

In the case of fee-for-service recipients or for mental health and antiretroviral drugs covered by the State, the number to call to obtain authorization to dispense an emergency supply is 800-932-3918. During the 72 -hour window, the pharmacist is to contact the prescriber who must obtain prior authorization before the remainder (continued on next page)

## HIV/AIDS Drugs to be Carved Out of HealthChoice Effective January 1, 2008

Beginning January 1, 2008 all antiretroviral medications will be carved-out of the HealthChoice managed care benefit and must be billed fee-for-service (BIN 610084, PCN DRMDPROD, Group ID MDMEDICAID). After that date, do not bill any antiretroviral medications to the HealthChoice Managed Care Organizations (MCOs) or their Pharmacy Benefit Managers (PBMs). Claims should be processed fee-for-service, just as claims for other carved-out drugs, such as mental health drugs, are currently billed.

Claims for other medications, except those already carved-out, should continue to be billed to the MCOs or their pharmacy PBMs. This includes antibiotics associated with treatment of secondary infections in HIV/AIDS patients. Only the antiretroviral medications should be billed fee-for-service.

A $\$ 1.00$ co-pay will be associated with all claims for antiretroviral therapy except for the exceptions below. Please note that some of the recipients receiving antiretrovirals did not previously have a co-payment. No co-payment is required if the patient is:

- Younger than 21 years old
- Pregnant
- An inpatient in a long-term care facility.


## In This Issue

Emergency Supply of Medication ..... 1
HIV AIDS Drugs Co-Pay Notice .....  1
Atypical Antipsychotic Agents ..... 2
Step Therapy Criteria for Zyprexa ${ }^{\circledR}$ ..... 2
Emergency Supply of Medication (continued). ..... 2
Important Telephone Numbers. ..... 2
Non-Formulary Emergency Supply Policies andProcedures3
Pharmacy Briefs ..... 4

## Atypical Antipsychotic Agents Being Added To The Preferred Drug List

One of the goals of the Maryland Medicaid Pharmacy Program is to ensure that recipients receive optimal drug therapy at the lowest reasonable cost. Atypical antipsychotic agents have improved the lives of many Maryland Medicaid recipients. However, the cost of these agents represents the single highest expenditure for the Program. For State fiscal year 2007, approximately $\$ 70$ million was spent on claims for atypical antipsychotic agents, which represents over $30 \%$ of the entire annual fee-for-service pharmacy budget.

In an effort to maximize the effectiveness of these agents while controlling costs and avoiding adverse patient outcomes, as of January 1, 2008 the atypical antipsychotic agents will be added to the Maryland Medicaid Preferred Drug List.

All atypical antipsychotic agents will be included on the Maryland Medicaid Preferred Drug List (PDL). However, step therapy criteria have been developed for Zyprexa ${ }^{\circledR}$ due to the potential for adverse effects related to weight gain, diabetes control and hyperlipidemia. The Food and Drug Administration recently required the manufacturer of Zyprexa ${ }^{\circledR}$ to include additional warnings in the drug labeling regarding hyperglycemia, hyperlipidemia and weight gain. Step therapy criteria for Zyprexa ${ }^{\circledR}$ are included in the following article.

## Step Therapy Criteria For Zyprexa ${ }^{\circledR}$

Beginning January 1, 2008 step therapy criteria will be required for the use of Zyprexa ${ }^{\oplus}$. Six weeks of therapy with another atypical agent will be required prior to beginning therapy with Zyprexa ${ }^{\oplus}$. Patients already taking Zyprexa ${ }^{\oplus}$ will be able to continue on therapy without any prior authorization requirements. Prior authorization for initiation of Zyprexa ${ }^{\circledR}$ as first line therapy is available by calling 800-932-3918.

For those patients who require initial treatment with Zyprexa ${ }^{\oplus}$ as first line therapy, up to a 30 -day emergency supply of medication may be provided by the dispensing pharmacy. The number to call to obtain authorization to dispense a 30 -day emergency supply is 800-932-3918.

After the initial 30 days, prior authorization will be required for the patient to continue on the drug. The pharmacist is to contact the prescriber to obtain prior authorization before the 30-day emergency supply of the medication is completely utilized by the patient. After prior authorization has been established, the pharmacist may dispense any refills that may be authorized.

If you have questions regarding this initiative please contact the Maryland Medicaid Pharmacy Program at 410-767-1455.

## Emergency Supply of

 Medications (continued from previous page)of the prescription can be dispensed. With the exception of a prescription for a Schedule II controlled substance, after prior authorization has been established, the pharmacist can dispense the remainder of the prescription.

The Maryland Medicaid Program allows a pharmacist to dispense a 72 -hour supply of a Schedule II controlled substance. To comply with Maryland Pharmacy law and to prevent abuse of these drugs, the pharmacist must keep the prescription order and the member must return to the doctor to get a new prescription order to receive the full supply of medication.

Refills for 30-day emergency supplies of Zyprexa ${ }^{\oplus}$ may not br given unless prior authorization has been obtained.

Further details about implementation of this policy, including co-pay and dispensing fee information, may be found in Advisory 5B, at bttp://www.dhmb.state.md.us/mmal mpap/provadv.html.

## Telephone Numbers

## ACS Technical Assistance and Preauthorizations

 1-800-932-3918 24 hours a day 7 days a week
## Other Telephone Numbers:

## Maryland Medicaid <br> Pharmacy Access Hotline

1-800-492-5231 (select option three)
Monday - Friday 8:00 am to 5:00 pm
Kidney Disease Program
1-410-767-6787 or 5002
Monday - Friday, 8:00 am to 5:00 pm

Breast \& Cervical Cancer<br>Diagnosis Treatment<br>1-410-767-6787<br>Monday - Friday 8:00 am to $5: 00 \mathrm{pm}$

Maryland AIDS Drug<br>Assistance Program<br>1-410-767-6535<br>Monday - Friday, 8:30 am to $4: 30 \mathrm{pm}$

 Provider inquiries／complaints－HealthChoice Provider／PAC Hotline 1－800－766－8692，Option 4



| －ssəoo．Id OOL әप <br>  <br>  <br>  <br>  <br>  ：ய！̣！ <br>  <br>  <br>  | ソəәм ．ıəd sKep L－s．ınoч $\dagger$ ¢ | $\begin{array}{r} \text { LSSI-ZZ6-008-I } \\ \text { ЧІ Геән оорәW } \end{array}$ |  |
| :---: | :---: | :---: | :---: |
|  <br>  <br>  |  |  |  |
|  <br>  <br>  |  | Et0I－6I8－888－I <br>  |  |
|  |  ud00：s－ue0e：8 ！！ $\boldsymbol{H}^{-}$uON | ZZLI－S06－008－I IO 00Zて－をと6－0It IEISpow |  |
|  <br>  <br>  | ソәәм rad sKep L－S．ınou $\dagger$ ¢ |  |  |
|  <br>  <br>  | Yəom ．rod sKep L－s．nnoy $\dagger \tau$ | 乙 uo！̣do＇$\downarrow$ ¢ $88-\varepsilon \subseteq 6^{-008-1}$ <br>  <br>  | sue！gisfyd pueliniesn |
|  <br>  <br>  <br>  <br>  |  <br>  |  |  |
|  <br>  <br>  <br>  <br>  |  |  | อ．IE？ ЧПеән К．лиәлоつ سo．ly ueId puourea |
|  <br>  | ソәәм е sКер $\angle-\operatorname{sinoy~} \dagger$ ¢ | ```&ItS-SカE-008-I```  |  |
|  <br>  | S．Inoy deqfe |  |  |
|  <br>  <br>  |  <br>  <br>  |  | ә．лед Kı！unuwo <br>  |
|  <br>  | ODW ． 10 Wgd $10 J$ uo！pe．əədo jo s．InoH |  <br>  <br>  | （ODN） иоџ̣еz！uesi．iO <br>  |

## 



## Pharmacy Briefs

## Maryland Medicaid Pharmacy Program Website

The Maryland Medicaid Pharmacy Program has developed a website which contains information regarding the Pharmacy Program, including past issues of the Pharmacy Newsletter, links to Advisories, Transmittals, the Preferred Drug List, MCO Formularies and information regarding upcoming continuing education programs. The website can be viewed at www.marylandmedicaidpharmacyinformation.com.

## DHMH E-mail "Advisory"

The Department of Health and Mental Hygiene Maryland Medicaid Pharmacy Program (MMPP) utilizes an e-mail notification service called an "Advisory" to give the pharmacy community important timely information. If you are currently not receiving e-mail Advisories through a pharmacy organization you belong to, please contact the MMPP representative at 410-767-1455.

## Unacceptable Prescriber DEA Numbers

All claims submitted to the point-of-service (POS) claims processor for the Maryland Medicaid Pharmacy Programs must contain the Prescriber's DEA number. DO NOT submit claims using DEA numbers that begin with "X_". These numbers are assigned by the Drug Enforcement Administration to Prescribers who are authorized to write prescriptions for Suboxone ${ }^{\circledR}$. If claims are submitted with these special Suboxone ${ }^{\circledR}$ prescriber DEA numbers, they will be denied at POS. Pharmacies should also make every effort to use the correct DEA number assigned to prescribers. When an improper DEA number is used, the prescription claim is considered invalid.

##   YOOपS Uห.8วN uMOIG-Кวાеว عлב 10ท! <br> :HHVLS <br>    <br> SStl-L9L-OLt  <br>  

 s.apusshans.u.teyd

